VTRS Q3 2022 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena

VTRSViatris Inc.

$17B

Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.1B-10.1% YoY

Gross Profit

$1.7B42.9% margin

Operating Income

$560M13.7% margin

Net Income

$354M8.7% margin

EPS (Diluted)

$0.29

QoQ Revenue Growth

-0.9%

Cash Flow

Operating Cash Flow

$869M

Free Cash Flow

$753M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$48.7B

Total Liabilities

$29.5B

Stockholders' Equity

$19.2B

Cash & Equivalents

$647M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.1B	$4.5B	-10.1%
Gross Profit	$1.7B	$1.6B	+11.1%
Operating Income	$560M	$358M	+56.6%
Net Income	$354M	$312M	+13.7%

Revenue Segments

Brands

$2.5B62%

Generics

$1.2B30%

Complex GX and Biosimilars

$320M8%

Geographic Segments

Developed Markets Segment

$2.4B60%

Emerging Markets Segment

$679M17%

Greater China Segment

$574M14%

Japan, Australia and New Zealand Segment

$383M9%